Ethoxyquin (Synonyms: NSC 6795) |
| رقم الكتالوجGC32965 |
إيثوكسيكوين هو أحد مضادات الأكسدة التي استخدمت في علف الحيوانات لسنوات عديدة ، وكذلك مثبط لبروتين الصدمة الحرارية 90 (Hsp90)
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 91-53-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ethoxyquin is an antioxidant which has been used in animal feed for many years and also an inhibitor of heat shock protein 90 (Hsp90).
Ethoxyquin (EQ) does not block Paclitaxel's (PTX's) ability to induce cell death in 4 different breast cancer cell lines. Results demonstrate that only when Hsp90 level is down regulated is neuroprotec-tion provided by Ethoxyquin (EQ) no longer seen[2]. It is found that Ethoxyquin provides neuroprotection with a best efficacy range from 30 to 300 nM. It is interesting to note that higher (μM) concentrations of Ethoxyquin do not provide further neuroprotection and in fact at these higher concentrations Ethoxyquin loses its neuroprotective effects[3].
Ethoxyquin (EQ) provides a dose-dependent neuroprotection. Although all 3 doses of Ethoxyquin provide partial neuroprotection against reduction in intraepidermal nerve fiber density, the peak efficacy is with the 75 μg/kg dose[2]. Rats treated with Ethoxyquin (EQ) alone or control vehicle treated rats gain weight as expected under normal physiological conditions[3].
[1]. Sadikot T, et al. Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay Drug Dev Technol. 2013 Oct;11(8):478-88. [2]. Zhu J, et al. Ethoxyquin prevents chemotherapy-induced neurotoxicity via Hsp90 modulation. Ann Neurol. 2013 Dec;74(6):893-904. [3]. Zhu J, et al. Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity. Sci Rep. 2016 Jun 28;6:28861.
Kinase experiment: | To evaluate the impact of Ethoxyquin (EQ) on Paclitaxel’s (PTX’s) ability to kill breast cancer cells, conditions for culturing 4 cancer cell lines and measuring the ATP levels are optimized for the 96-well plate format. Briefly, 1,500 cells/well in media are plated in 96-well plates for 24 hours. Constant concentrations of PTX with or without Ethoxyquin are added to the wells for another 24 hours. Cellular ATP levels are measured using kit according tomanufacturer ’s protocol[2]. |
Cell experiment: | Briefly, DRGs are harvested from embryonic day 14.5 rats according to standard protocols, then cells are plated onto collagen-coated glass coverslips and allowed to extend neurites for 24 hours in media (Neurobasal medium, 50 mM pencillin-streptomycin (PS), 0.2% FBS, 0.5 mM glutamine, 1×B-27 supplement, 0.2% glucose,10 ng/mL glial cell line-derived neurotrophic factor). Ethoxyquin (EQ) or vehicle control is added to the wells for another 24-hour incubation. DRG cells are fixed with 4% paraformaldehyde and stained with anti-βIII-tubulin antibody to delineate the axons. Axon lengths are measured in multiple fields using a random sampling method[2]. |
Animal experiment: | To examine the effect of Ethoxyquin (EQ) on Paclitaxel’s (PTX’s) ability to reduce tumor burden in vivo, a mouse model in which breast cancer cell line SUM-159 (3×106 tumor cells suspended in phosphate-buffered saline in a final volume of 0.15 mL) is injected subcutaneously into adult male nude mice. When the tumor size reaches 5 mm in diameter, the animals are randomly assigned to PTX or PTX with Ethoxyquin groups. Ethoxyquin is given by intraperitoneal administration on a daily basis for 3 weeks. At the end of 3 weeks, animals are euthanized and tumor size and weight are measured (n=5 per group)[2]. |
References: [1]. Sadikot T, et al. Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay Drug Dev Technol. 2013 Oct;11(8):478-88. | |
| Cas No. | 91-53-2 | SDF | |
| المرادفات | NSC 6795 | ||
| Canonical SMILES | CC1=CC(C)(C)NC2=C1C=C(OCC)C=C2 | ||
| Formula | C14H19NO | M.Wt | 217.31 |
| الذوبان | DMSO : ≥ 50 mg/mL (230.09 mM);Water : < 0.1 mg/mL (insoluble) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.6017 mL | 23.0086 mL | 46.0172 mL |
| 5 mM | 0.9203 mL | 4.6017 mL | 9.2034 mL |
| 10 mM | 0.4602 mL | 2.3009 mL | 4.6017 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 36 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *